A Phase 1 interventional study of ABX-002 in Healthy, sponsored by Autobahn Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by Autobahn Therapeutics, Inc. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to assess the bioequivalence (BE) between the liquid formulation and the new solid formulation of ABX-002 under fasting conditions and to evaluate the effect of food on the pharmacokinetics (PK) of the new solid formulation of ABX-002.This study design is consistent with FDA guidelines for the assessment of BE.
This was an open label, randomized, single dose, three-way crossover BE and food-effect study. Therefore, the total number of participants in this study was 18.
Autobahn Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sequence ABC
Drug: ABX-002
Sequence BCA
Drug: ABX-002
Sequence CAB
Drug: ABX-002
Sequence ACB
Drug: ABX-002
Sequence BAC
Drug: ABX-002
Sequence CBA
Drug: ABX-002
ABX-002 was supplied as a solution and solid dose form.
Evaluate the bioequivalence between ABX-002 liquid formulation and ABX-002 solid formulation in healthy adult participants.
Change in Area Under the Curve from time zero to the last quantifiable concentration for ABX-002 and LL-340001
Time frame: 8 weeks
Evaluate the bioequivalence between ABX-002 liquid formulation and ABX-002 solid formulation
Change in Area Under the Curve from time zero to infinity for ABX-002 and LL-340001
Time frame: 8 weeks
Evaluate the bioequivalence between ABX-002 liquid formulation and ABX-002 solid formulation
Change in Peak Plasma Concentration for ABX-002 and LL-340001
Time frame: 8 weeks
Evaluate the effect of a high-fat meal on the PK of ABX-002 solid formulation in healthy adult participants
Change in Change in Area Under the Curve from time zero to the last quantifiable concentration for ABX-002 and LL-340001
Time frame: 8 weeks
Evaluate the effect of a high-fat meal on the PK of ABX-002 solid formulation in healthy adult participants
Change in Area Under the Curve from time zero to infinity for ABX-002 and LL-340001
Time frame: 8 weeks
Evaluate the effect of a high-fat meal on the PK of ABX-002 solid formulation in healthy adult participants
Change in Peak Plasma Concentration for ABX-002 and LL-340001
Time frame: 8 weeks
Evaluate the safety and tolerability of 3 total doses of ABX-002 in healthy adult participants.
Incidence and severity of treatment-emergent adverse events to ABX-002 will be measured
Time frame: 8 weeks
Ran from Jan 2025 to primary completion in Feb 2025, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elunetirom
Autobahn Therapeutics, Inc.